How we treat mature B-cell neoplasms (indolent B-cell lymphomas)

Table 1 Reported radiation-associated toxicities from two randomized, phase 3 trials

Study	Study population	Acute toxicities			Late toxicities
Study	Study population	Toxicity	All grades (%)	Moderate–severe grade (%)	Toxicity	All grades (%)	Moderate–severe grade (%)
BNLI Dose Reduction [29] (2011)	179 patients with indolent NHL receiving 24 Gy as part of randomized, phase III dose reduction study	Erythema	34	8	Xerostomia	23	8
		Mucositis	25	11	Skin fibrosis	17	2
		Dry desquamation	13	1	Alopecia	16	3
		Nausea/ vomiting	11	4	Mucosal injury	9	4
		Diarrhea	9	1	Cutaneous telangiectasia	8	0

		Toxicity	Grade 3 (%)	Toxicity	Grade 3 (%)
FORT Study [125] (2014)	299 patients with MZL or FL receiving 24 Gy as part of randomized phase III non-inferiority study of very low dose RT	Any	2.8	Any	1.4
		Mucositis	0.7	Mucosal injury	0.7
		Fatigue	0.7	Fatigue	0.4
		Pain in irradiated area	0.4	Pressure sore	0.4
		Diarrhea	0.4	Constipation	0.4

This table outlines the toxicities associated with radiation therapy based on two randomized, phase 3 trials. Note that the FORT study only reported severe toxicities and likely used more modern technology, while the BNLI study reported toxicities of all grades and is based upon data using older techniques
FL follicular lymphoma, MZL marginal zone lymphoma, NHL non-Hodgkin lymphoma, RT radiotherapy

ISSN: 1756-8722